ISBN: 978-0-6450017-5-4
Exon Publications, Brisbane, Australia

Simon RJ Bott, MD, FRCS, FEBU (Editor)
Urology Department, Frimley Park Hospital, Frimley, Camberley GU16 7UJ, UK

Keng Lim Ng, MBBS, PhD, FRCS (Editor)
Urology Department, Frimley Park Hospital, Frimley, Camberley GU16 7UJ, UK


Prostate cancer is a life-altering diagnosis, not just for patients, but for their loved ones as well. Once, prostate cancer was most frequently diagnosed in men in their 60s and 70s; with increasing use of imaging modalities and PSA testing, the incidence is on the rise, and we are now seeing men in their 40s with the disease. This poses a challenge for clinical management depending on the stage of the disease—from watchful waiting or active surveillance to aggressive treatment with the risk of therapeutic nihilism. Despite being one of the most common cancers in Western men, its natural history, prognosis, and treatment are poorly understood. This book brings together a select faculty of experts to present a comprehensive view of the current state and future perspectives of prostate cancer. There are ten chapters in the book—the first four cover our present knowledge and understanding of the disease, the following three explore new advancements and treatments, particularly looking at overcoming resistance to therapy, and the remaining three chapters focus on specific molecules with the potential to become drug targets. We all have much to learn about prostate cancer. This book is aimed primarily at clinicians and scientists, but many areas will also be of interest to the layperson.


Published: 2021-05-27


Richard Hindley, MBCHB, MSC, FRCS

Page vii


Simon RJ Bott, MD, FRCS, FEBU, Keng Lim Ng, MBBS, PHD, FRCS

Pages ix-x

The Etiology of Prostate Cancer

Keng Lim Ng, MBBS, PHD, FRCS

Pages 17-27

The Pathogenesis of Prostate Cancer

Toby BJ Murray, MD, MSC, MSCR

Pages 29-41

Current Diagnostics for Prostate Cancer

Danielle Whiting, MRCS, Simon RJ Bott, MD, FRCS, FEBU

Pages 43-57

Combination Treatment Options for Castration-Resistant Prostate Cancer

Dannah R. Miller, PHD, Matthew A. Ingersoll, PHD, Benjamin A. Teply, MD, Ming-Fong Lin, PHD

Pages 59-79

Theranostics in Metastatic Castrate Resistant Prostate Cancer

Mariza Vorster, MBCHB, MMED, MPHARMMED, FCNP, PHD, Machaba Michael Sathekge, MBCHB, MMED, FAMS, PHD

Pages 81-96

Adenocarcinoma of the Prostate: Future Directions for Translational Science

Tao Wang, PHD, Brain Lewis, PHD, Ameer Elaimy, PHD, Marcus Ruscetti, PHD, Mitchell Sokoloff, MD, Kriti Mittal, MD, Thomas J. FitzGerald, MD

Pages 97-112

Revisiting the Role of p53 in Prostate Cancer

Miriam Teroerde, MD, Cathleen Nientiedt, MD, Anette Duensing, MD, Markus Hohenfellner, MD, Albrecht Stenzinger, MD, Stefan Duensing, MD

Pages 113-123

MUCIN 1 in Prostate Cancer

Anil Kapoor, MD, Yan Gu, BSC, Xiaozeng Lin, PHD, Jingyi Peng, BSC, Pierre Major, MD, Damu Tang, MSC, PHD

Pages 125-138

The Usefulness of STEAP Proteins in Prostate Cancer Clinical Practice

Sandra Rocha, MSC, Jorge Barroca-Ferreira, MSC, Luís Passarinha, PHD, Sílvia Socorro, PHD, Cláudio Maia, PHD

Pages 139-153


Pages 155-157